Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MPDL3280A + HIGRT in Metastatic NSCLC
NCT02463994Phase 1Completed
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- Oct 2015
- Primary completion
- Nov 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of atezolizumab in non-small cell lung cancer (NSCLC), sponsored by University of Michigan Rogel Cancer Center. Primary endpoint: Number of participants that respond to a combination of HIGRT and MPDL3280A at 5 years. Started Oct 2015; status: completed.
02
Drugs
atezolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02463994.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02463994.